I am a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. My background in public health, with a focus on clinical investigation and epidemiology, has provided me with a clear understanding of the study design and validation techniques which are essential to the study of these topics. I currently serve as the Director of Early Drug Development and Phase I trials in our Department and I am the principal investigator of multiple novel treatment trials for gynecologic cancers. In this position, I am the PI for a multi-arm Phase Ib trial combining PARP inhibition with agents that target the PI3K pathway in endometrial and ovarian cancer. This trial includes pre and post-treatment biopsies to identify markers of response and resistance. Further, I developed the first window of opportunity study of BMN-678, a PARP inhibitor, in untreated advanced ovarian cancer. In addition, I am a project co-PI for our SPORE in uterine cancer. As such, I served as the PI for a national GOG/CTEP trial (GOG229O) to determine the association of molecular aberrations in the PI3K/AKT and RAS/RAF/MEK pathways with clinical activity of targeted agents in the treatment of endometrial cancer.